Cinvanti: A Comprehensive Guide to Its Uses, Dosage, Demographics, Side Effects, Interactions, and Generic Options Chemotherapy-induced nausea and vomiting (CINV) is a common and debilitating side effect of cancer treatment. While there are several anti-emetics available to alleviate CINV, some patients still experience breakthrough symptoms. This is where Cinvanti comes in. In this article, we will dive into what Cinvanti is, how it works, its uses, dosages, demographics, side effects, interactions, and generic options. What is Cinvanti? Cinvanti (aprepitant injectable emulsion) is a highly selective, high-affinity antagonist of the neurokinin-1 (NK-1) receptor. This receptor is involved in the signal transduction pathway for nausea and vomiting. Cinvanti is a prescription-only medication that is administered by a healthcare provider. How does Cinvanti work? Cinvanti works by blocking the NK-1 receptors in the brain that are involved in the nausea and vomiting response. By doing so, Cinvanti helps reduce the severity and frequency of CINV. What are the uses of Cinvanti? Cinvanti is indicated for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic chemotherapy (HEC) and moderately emetogenic chemotherapy (MEC). What is the dosage of Cinvanti? The recommended dosage of Cinvanti is a single 130 mg intravenous infusion over 30 minutes on Day 1 of the chemotherapy regimen. It can be given before or after chemotherapy. No dosage adjustment is needed for elderly patients or those with mild to moderate hepatic impairment. Cinvanti is not recommended for use in patients with severe hepatic impairment. What are the demographics of Cinvanti use? Cinvanti is approved for use in adults aged 18 years and older. It is well-tolerated in both men and women and across different races. However, there have been limited studies on its safety and efficacy in pregnant or breastfeeding women. What are the side effects of Cinvanti? The most common side effects associated with Cinvanti use are fatigue, hiccups, constipation, and abdominal pain. Other adverse reactions include dizziness, headache, fever, infusion site reactions, and changes in taste or smell. Less common but serious side effects include anaphylaxis and an increase in liver enzymes. What are the interactions with Cinvanti? Cinvanti may interact with medications that are substrates, inhibitors, or inducers of CYP3A4, such as dexamethasone and rifampin. It may also interact with drugs that prolong the QT interval, potentiate the QT interval, and increase the risk of torsade de pointes, like ondansetron and dolasetron. What are the generic options for Cinvanti? There are currently no generic options for Cinvanti. However, there are several other NK-1 receptor antagonists available, such as fosaprepitant and rolapitant, that work similarly to Cinvanti. In conclusion, Cinvanti is a highly selective NK-1 receptor antagonist that is effective in preventing CINV associated with HEC and MEC. Its dosage, demographics, side effects, interactions, and generic options must be taken into consideration when prescribing and administering this medication. Patients who still experience breakthrough symptoms or intolerable side effects should consult their healthcare provider for alternative anti-emetics.